Rivaroxaban is superior to warfarin in reducing vascular mortality and bleeding-related hospitalisations in patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes. Research presented recently at the ACC.21, and published in Cardiovascular Diabetology, comprised electronic health data from 32,000 patients newly started on rivaroxaban (15 or 20 mg daily) and 84,000 patients newly started ...
DOAC reduces risk of vascular death by 10% in people with AF and T2D
By Mardi Chapman
26 Jun 2021